U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING
REJECTION OVER A "PRIOR" PATENT

Docket Number (Optional) 5566

In re Application of: Aerts. Application No. 10/595,584

Filed: May 23, 2006

For: Use of Deoxynojirimycin Derivative or a Pharmaceutical Salt Thereof

The owner*, <u>Genzyme Corporation</u>, of <u>100</u> percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of **prior patent** No. <u>US7,528,153</u> as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said **prior patent** is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:

Terminal disclaimer fee under 37 CFR 1.20(d)		
	Isabelle A. S. Blundell, Ph.D. ———————————————————————————————————	
	Signature	Date
2. The undersigned is an attorney of record.	Reg. No. 43,321 Leabellet & Lundell	11/9/09
information and belief are believed to be true; and statements and the like so made are punishable b	e herein of my own knowledge are true and that all sta further that these statements were made with the knowled by fine or imprisonment, or both, under Section 1001 of Tit may jeopardize the validity of the application or any patent is	lge that willful false
For submissions on behalf of a business etc.), the undersigned is empowered to act	s/organization (e.g., corporation, partnership, university, g t on behalf of the business/organization.	overnment agency
Check either box 1 or 2 below, if appropriate.		
	ion of its full statutory term as presently shortened by any te	rminal disclaimer.
has all claims canceled by a reexamination cert is reissued; or	incommed under 57 GTX 1.321,	
is found invalid by a court of competent jurisdict is statutorily disclaimed in whole or terminally di	tion;	•
is held unenforceable;		

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA22313-1450.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).

Form PTO/SB/96 may be used for making this certification. See MPEP § 324.